Similar to wise buying decisions, exiting certain underperformers at the right time helps maximize portfolio returns. Selling off losers can be difficult, but if both the share price and estimates are falling, it could be time to get rid of the security before more losses hit your portfolio.
One such stock that you may want to consider dropping is Insulet Corporation (PODD), which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year. A Zacks Rank #4 (Sell) further confirms weakness in PODD.
A key reason for this move has been the negative trend in earnings estimate revisions. For the full year, we have seen 12 estimates moving down in the past 30 days, compared with no upward revisions. This trend has caused the consensus estimate to trend lower, going from a loss of 40 cents a share a month ago to its current level of a loss of 99 cents.
Also, for the current quarter, Insulet has seen 10 downward estimates revisions versus 0 revisions in the opposite direction, dragging the consensus estimate down to a loss of 26 cents a share from a loss of 5 cents over the past 30 days.
The stock also has seen some pretty dismal trading lately, as the share price has dropped 15.3% in the past month.
So it may not be a good decision to keep this stock in your portfolio anymore, at least if you don’t have a long time horizon to wait.
If you are still interested in the Medical Products industry, you may instead consider a better-ranked stock– NuVasive (NUVA). The stock currently holds a Zacks Rank #1 (Strong Buy) and may be better selection at this time.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
INSULET CORP (PODD): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research